Supplementary Material for: Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer

<i>Background: </i>Taxanes are effective in treating metastatic breast cancer. Liposomal doxorubicin (LD) is as effective as doxorubicin but less toxic. <i>Patients and Methods: </i>This phase II trial assessed the combination of LD and docetaxel (D). Between 12/2002 and 9/2005, 12 women received monthly LD (30 mg/m<sup>2</sup>) and weekly D (30 mg/m<sup>2</sup>). Cycles were continued until progression or toxicity. Primary outcome was time to progression. Secondary endpoints included response rate, time to treatment failure, duration of response, survival, and toxicity. <i>Results: </i>Median age was 49 (31–60) years. 9 (75%) patients had estrogen receptor-positive or progesterone receptor-positive tumors. 5 (41.7%) women had her-2/neu-positive tumors. 4 women stopped participation due to toxicity, and 7 due to progression. 8 (67%) participants (95% confidence interval (CI) 51.6–94.5%) had a partial response, and 2 (16.7%) had stable disease. Median time to progression was 9.6 months (95% CI 4.7– 12.2). Median time to treatment failure was 6.5 months (95% CI 4.4–10.5). Median survival was 22.1 months (95% CI 9.6– 40.8). Median duration of partial response was 2.7 months (95% CI 2.4–10.5). 10 (83%) women experienced grade 3/4 toxicities: neutropenia 3 (25%), infection 3 (25%), stomatitis 5 (41.7%), nausea 2 (16.7%), vomiting 1 (8.3%), dyspnea 2 (16.7%), pericardial effusion 1 (8.3), and palmarplantar erythrodysesthesia 1 (8.3%). <i>Conclusions: </i>LD and D resulted in an encouraging response and unacceptable toxicities.